GenMark Diagnostics Appoints Dr. James Fox as Chairman of the Board
August 11 2014 - 4:05PM
Business Wire
Christopher Gleeson Retires from the Board
to Attend to Personal Health Matters
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading
provider of automated, multiplex molecular diagnostic testing
systems, today announced the appointment of Dr. James Fox as
Chairman of the Board. Dr. Fox is replacing Christopher Gleeson,
who is retiring from the Board to attend to personal health
matters.
“Being part of building GenMark from a very small start into the
business it is today, particularly with the quality of our senior
leadership team, is a source of great satisfaction for me. I have
every confidence that GenMark will continue to grow and develop
into the leading molecular diagnostics company that I envisaged.
Equally, I am very pleased to hand over to Jim Fox who I think is a
great fit for the needs of the company going forward,” said
Gleeson.
Dr. Fox, age 62, has served on the Company’s Board since
September 2010. Dr. Fox led the start-up of Invetech, an
Australian contract research and development company that
specializes in healthcare products and complex instruments for
international markets. Dr. Fox transformed Invetech into the ASX
listed Vision Systems Ltd Group with its principal activity in
In-Vitro diagnostics through its Vision BioSystems Ltd subsidiary.
Vision Systems was ultimately acquired by Danaher Corporation in
2006. Dr. Fox left the Vision Systems Group at the completion of
its acquisition by Danaher in December 2006 and took up a number of
board roles around the world. He currently serves as Chairman of
the Board of Biota Pharmaceuticals, Inc., as a director of Air New
Zealand Ltd. (he retires from the Air New Zealand board in August
this year), as a director of TTP Group plc (UK) and as a director
of MS Research Australia, a not-for-profit organization aimed at
financing public multiple sclerosis research. Dr. Fox received
his Bachelor’s, Master’s and Ph.D. degrees in engineering from the
University of Melbourne.
“Chris has been a friend, mentor, and close advisor to me, the
GenMark leadership team, and the members of the Board of Directors.
His passion to build a great business and incredible energy level
will be missed and we wish Chris and his family the very best,”
said Hany Massarany, president and chief executive officer,
GenMark. “Dr. Jim Fox brings a vast amount of experience in the
medical device and healthcare industries and we are pleased to have
him play a key role as we launch our ePlex™ sample to answer
platform.”
“As an outstanding leader and a long time personal friend, I
will miss Chris around the Board table and I am honored to take up
the role of Chairman,” said Fox. “This is a very significant period
in the company’s history as we finalize the development of our new
sample to answer platform, while at the same time still driving
results from our existing products,” said Fox. “GenMark’s
proprietary and core eSensor® detection technology is a key
competitive differentiator and our leadership team and Board remain
focused on successfully executing our vision of establishing
GenMark as a world leading molecular diagnostics company.”
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and
measure DNA and RNA targets to diagnose disease and optimize
patient treatment. Utilizing GenMark’s proprietary eSensor®
detection technology, GenMark’s eSensor® XT-8 system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA
cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory
Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity
Test. A number of other tests, including HCV Genotyping, 2C19
Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements regarding
events, trends and business prospects, which may affect our future
operating results and financial position. Such statements,
including, but not limited to, those regarding the timely
completion of our ePlex™ system and related assay development
projects, are all subject to risks and uncertainties that could
cause our actual results and financial position to differ
materially. Some of these risks and uncertainties include, but are
not limited to, our ability to successfully develop and
commercialize our ePlex™ system and its related test menu,
constraints or inefficiencies caused by unanticipated acceleration
and deceleration of customer demand, our ability to successfully
expand sales of our product offerings outside the United States,
and third-party payor reimbursement to our customers, as well as
other risks and uncertainties described under the “Risk Factors” in
our public filings with the Securities and Exchange Commission. We
assume no responsibility to update or revise any forward-looking
statements to reflect events, trends or circumstances after the
date they are made.
GenMark Diagnostics, Inc.Hany MassaranyPresident/Chief Executive
Officer760-448-4358
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Apr 2023 to Apr 2024